DK3708192T3 - Etherphospholipidforbindelser til behandling af cancer og billeddannelse og detektering af cancerstamceller - Google Patents

Etherphospholipidforbindelser til behandling af cancer og billeddannelse og detektering af cancerstamceller Download PDF

Info

Publication number
DK3708192T3
DK3708192T3 DK20172745.0T DK20172745T DK3708192T3 DK 3708192 T3 DK3708192 T3 DK 3708192T3 DK 20172745 T DK20172745 T DK 20172745T DK 3708192 T3 DK3708192 T3 DK 3708192T3
Authority
DK
Denmark
Prior art keywords
cancer
etherphospholipid
imaging
compounds
detection
Prior art date
Application number
DK20172745.0T
Other languages
English (en)
Inventor
Jamey P Weichert
Anatoly Pinchuk
Irawati Kandela
Marc Longino
William R Clarke
Original Assignee
Cellectar Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellectar Inc filed Critical Cellectar Inc
Application granted granted Critical
Publication of DK3708192T3 publication Critical patent/DK3708192T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0408—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A61N2005/1019—Sources therefor
    • A61N2005/1021—Radioactive fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/02—Radiation therapy using microwaves

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK20172745.0T 2009-06-12 2010-06-11 Etherphospholipidforbindelser til behandling af cancer og billeddannelse og detektering af cancerstamceller DK3708192T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18660009P 2009-06-12 2009-06-12
EP10786904.2A EP2440253B1 (en) 2009-06-12 2010-06-11 Alkyl phospholipid compounds for treating cancer and imaging and detection of cancer stem cells

Publications (1)

Publication Number Publication Date
DK3708192T3 true DK3708192T3 (da) 2023-11-06

Family

ID=43306617

Family Applications (2)

Application Number Title Priority Date Filing Date
DK20172745.0T DK3708192T3 (da) 2009-06-12 2010-06-11 Etherphospholipidforbindelser til behandling af cancer og billeddannelse og detektering af cancerstamceller
DK10786904.2T DK2440253T3 (da) 2009-06-12 2010-06-11 Alkylphospholipidforbindelser til behandling af cancer og billeddannelse og detektering af cancerstamceller

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK10786904.2T DK2440253T3 (da) 2009-06-12 2010-06-11 Alkylphospholipidforbindelser til behandling af cancer og billeddannelse og detektering af cancerstamceller

Country Status (8)

Country Link
US (3) US20100316567A1 (da)
EP (3) EP2440253B1 (da)
JP (2) JP6092624B2 (da)
DK (2) DK3708192T3 (da)
ES (2) ES2799411T3 (da)
RU (1) RU2012100765A (da)
SI (2) SI3708192T1 (da)
WO (1) WO2010144788A2 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005015687D1 (de) 2004-03-02 2009-09-10 Cellectar Inc Phospholipid-analoga für die behandlung von krebs
US8540968B2 (en) 2004-03-02 2013-09-24 Cellectar, Inc. Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
US8871181B2 (en) 2009-05-11 2014-10-28 Cellectar, Inc. Fluorescent phospholipid ether compounds, compositions, and methods of use
WO2010132428A1 (en) 2009-05-11 2010-11-18 Cellectar, Inc. Fluorescent phospholipid ether compounds, compositions, and methods of use
DK3708192T3 (da) 2009-06-12 2023-11-06 Cellectar Inc Etherphospholipidforbindelser til behandling af cancer og billeddannelse og detektering af cancerstamceller
WO2011031919A2 (en) * 2009-09-11 2011-03-17 Cellectar, Inc. Non-radioactive phospholipid compounds, compositions, and methods of use
WO2011031911A1 (en) * 2009-09-11 2011-03-17 Cellectar, Inc. Deuterated alkyl phospholipid compounds, compositions, and methods of use
WO2016073737A1 (en) 2014-11-05 2016-05-12 The Regents Of The University Of California Methods of selecting and isolating cancer stem cells
CN107708702A (zh) 2014-11-17 2018-02-16 塞勒克塔生物科学有限公司 磷脂醚类似物作为靶向癌症的药物载体
WO2017079535A1 (en) * 2015-11-06 2017-05-11 Wisconsin Alumni Research Foundation Long-lived gadolinium based tumor targeted imaging and therapy agents
JP2017135134A (ja) 2016-01-25 2017-08-03 パナソニックＩｐマネジメント株式会社 発光装置
US11147823B2 (en) 2016-07-13 2021-10-19 Wisconsin Alumni Research Foundation Phospholipid ether analogs for imaging and targeted treatment of pediatric solid tumors
KR102396334B1 (ko) 2016-07-18 2022-05-09 위스콘신 얼럼나이 리서어치 화운데이션 인 시츄 면역 조절 암 백신화를 위한 방사성할로겐화 제제
US11633506B2 (en) 2016-07-18 2023-04-25 Wisconsin Alumni Research Foundation Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
KR102396324B1 (ko) * 2016-07-25 2022-05-09 위스콘신 얼럼나이 리서어치 화운데이션 인 시츄 면역 조절 암 백신화를 위한 표적화된 방사선요법 킬레이트
US20180022768A1 (en) * 2016-07-25 2018-01-25 Wisconsin Alumni Research Foundation Radioactive phospholipid metal chelates for cancer imaging and therapy
KR102758660B1 (ko) * 2017-11-10 2025-01-22 위스콘신 얼럼나이 리서어치 화운데이션 면역요법에 대한 항-종양 면역 반응을 유도하기 위해 표적화된 방사선요법(trt)을 이용하는 방법
WO2019200017A1 (en) 2018-04-10 2019-10-17 Cellectar Biosciences, Inc. Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy
CN112118871A (zh) * 2018-04-10 2020-12-22 塞勒科塔生物科学公司 用于治疗癌症的磷脂醚类似物的分次给药
KR102973364B1 (ko) * 2019-10-10 2026-06-04 셀렉타 바이오사이언시스, 인코퍼레이티드 인지질-플라바글린 접합체 및 표적화된 암 치료를 위해 이를 사용하는 방법
IL291980A (en) * 2019-10-10 2022-06-01 Cellectar Biosciences Inc Fractionated Dose of a Phospholipid Ether Analogue for Cancer Treatment
CA3212963A1 (en) 2021-04-23 2022-10-27 Reinier HERNANDEZ Psma-targeting ligands with optimal properties for imaging and therapy
CA3220076A1 (en) * 2021-05-27 2022-12-01 Steven M. Larson Lesional dosimetry for targeted radiotherapy of cancer
KR102857415B1 (ko) * 2023-12-15 2025-09-10 주식회사 코솔러스 망간을 선택적으로 회수할 수 있는 혼합 용매 추출제 및 이를 사용한 망간 회수 방법

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925649A (en) * 1987-06-12 1990-05-15 The University Of Michigan Radioiodinated diacylglycerol analogues and methods of use
US4965391A (en) * 1987-10-23 1990-10-23 The University Of Michigan Radioiodinated phospholipid ether analogues
US5347030A (en) * 1987-10-23 1994-09-13 The Board Of Regents Of The University Of Michigan Radioiodinated phospholipid ether analogues and methods of using same
US5087721A (en) * 1987-10-23 1992-02-11 The University Of Michigan Radioiodinated phosphate esters
US5274113A (en) * 1991-11-01 1993-12-28 Molecular Probes, Inc. Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5369097A (en) * 1991-04-25 1994-11-29 The University Of British Columbia Phosphonates as anti-cancer agents
US5783170A (en) * 1991-11-27 1998-07-21 Diatide, Inc. Peptide-metal chelate conjugates
US5626654A (en) * 1995-12-05 1997-05-06 Xerox Corporation Ink compositions containing liposomes
WO1998024480A1 (en) 1996-12-04 1998-06-11 The Regents Of The University Of Michigan Radioiodinated phospholipid ether analogs and methods of using the same
US6255519B1 (en) * 1996-12-04 2001-07-03 Regents Of The University Of Michigan Radioiodinated phospholipid ether analogs and methods of using the same
US6503478B2 (en) * 1999-01-13 2003-01-07 Lightouch Medical, Inc. Chemically specific imaging of tissue
CA2370081C (en) 1999-06-24 2014-06-03 The University Of British Columbia Lpl variant therapeutics
JP2003088366A (ja) 2001-09-07 2003-03-25 Res Dev Found 膵臓島細胞におけるインシュリン発現を刺激する新しいホメオボックス因子
CA2487692A1 (en) 2002-05-29 2003-12-11 Immunomedics, Inc. Methods and compositions for radioimmunotherapy of brain and cns tumors
US7220539B1 (en) * 2002-06-12 2007-05-22 The Salk Institute For Biological Studies Protein kinase B/Akt modulators and methods for the use thereof
CA2539107A1 (en) 2003-09-19 2005-03-31 Arcturus Bioscience, Inc. Predicting breast cancer treatment outcome
US7829742B2 (en) 2003-12-22 2010-11-09 Johns Hopkins University Boronic acid aryl analogs
US8540968B2 (en) 2004-03-02 2013-09-24 Cellectar, Inc. Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
US7632644B2 (en) * 2004-03-02 2009-12-15 Cellectar, Inc. Imaging and selective retention of phospholipid ether analogs
DE602005015687D1 (de) 2004-03-02 2009-09-10 Cellectar Inc Phospholipid-analoga für die behandlung von krebs
WO2006014589A2 (en) * 2004-07-08 2006-02-09 Cellectar, Llc Virtual colonoscopy with radiolabeled phospholipid ether analogs
EP1729790A4 (en) * 2004-03-29 2009-09-30 Robin Polt AMPHIPATHIC GLYCOPEPTIDES
US20060115426A1 (en) * 2004-08-11 2006-06-01 Weichert Jamey P Methods of detecting breast cancer, brain cancer, and pancreatic cancer
US7041859B1 (en) * 2004-09-09 2006-05-09 University Of Tennessee Research Foundation Method for halogenating or radiohalogenating a chemical compound
MX2007007497A (es) 2004-12-20 2008-01-11 Cellectar Llc Analogos de fosfolipido eter para la deteccion y tratamiento del cancer.
WO2009005509A1 (en) 2006-08-15 2009-01-08 Cellectar, Inc. Near infrared-fluorescence using phospholipid ether analog dyes in endoscopic applications
US8022235B2 (en) 2007-06-01 2011-09-20 Cellectar, Inc. Compositions of phospholipid ether boronic acids and esters and methods for their synthesis and use
US7893286B2 (en) * 2007-06-01 2011-02-22 Cellectar, Inc. Method for the synthesis of phospholipid ethers
WO2009148623A2 (en) * 2008-06-05 2009-12-10 Stc.Unm Methods and related compositions for the treatment of cancer
GB0819280D0 (en) * 2008-10-21 2008-11-26 Gen Electric Imgaing and radiotherapy methods
WO2010132428A1 (en) * 2009-05-11 2010-11-18 Cellectar, Inc. Fluorescent phospholipid ether compounds, compositions, and methods of use
DK3708192T3 (da) 2009-06-12 2023-11-06 Cellectar Inc Etherphospholipidforbindelser til behandling af cancer og billeddannelse og detektering af cancerstamceller
WO2011031911A1 (en) * 2009-09-11 2011-03-17 Cellectar, Inc. Deuterated alkyl phospholipid compounds, compositions, and methods of use
WO2011031919A2 (en) * 2009-09-11 2011-03-17 Cellectar, Inc. Non-radioactive phospholipid compounds, compositions, and methods of use

Also Published As

Publication number Publication date
SI2440253T1 (sl) 2020-09-30
JP2016011303A (ja) 2016-01-21
JP6092624B2 (ja) 2017-03-08
US20160228588A1 (en) 2016-08-11
WO2010144788A2 (en) 2010-12-16
ES2959862T3 (es) 2024-02-28
EP2440253B1 (en) 2020-05-13
US9339564B2 (en) 2016-05-17
EP4248999A2 (en) 2023-09-27
US20130343991A1 (en) 2013-12-26
EP3708192A1 (en) 2020-09-16
EP3708192B1 (en) 2023-08-02
ES2799411T3 (es) 2020-12-17
US10004818B2 (en) 2018-06-26
SI3708192T1 (sl) 2023-12-29
US20100316567A1 (en) 2010-12-16
DK2440253T3 (da) 2020-07-20
EP4248999A3 (en) 2023-11-15
RU2012100765A (ru) 2013-07-20
EP2440253A2 (en) 2012-04-18
JP2012530063A (ja) 2012-11-29
EP2440253A4 (en) 2016-01-13
WO2010144788A3 (en) 2014-03-20

Similar Documents

Publication Publication Date Title
DK2440253T3 (da) Alkylphospholipidforbindelser til behandling af cancer og billeddannelse og detektering af cancerstamceller
DK2632954T4 (da) Midler og fremgangsmåder til behandling af dlbcl
DK2398902T3 (da) Fremgangsmåder og sammensætninger til diagnosticering og behandling af cancer
DK2414507T3 (da) Mutanter af aktiveringsinduceret cytidin-deaminase (aid) og til anvendelsesfremgangsmåder
DK2340042T3 (da) Fremgangsmåder og præparater til behandling af cancer
DK2155188T3 (da) Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft
DK2473510T3 (da) Jak-2-hæmmere og anvendelse heraf til behandling af myeloproliferativesygdomme og cancer
EP2479558A4 (en) RADIATION DETECTOR
DK2298099T3 (da) Indsats til dampgennemtrængelige og vandtætte såler
DK2446246T3 (da) Indretning og fremgangsmåde til udvælgelse af partikler
DK2435432T6 (da) Apoptose-inducerende midler til behandling af cancer og immune og autoimmune sygdomme
DK2507211T3 (da) Apoptosefremkaldende midler til behandling af cancer og immun- og autoimmun-sygdomme
DK3622883T3 (da) Indførerer til medicinsk indretning og fremgangsmåder til at indføre og anvende medicinske indretninger
DK3128014T3 (da) Midler og fremgangsmåder til sterilisering af biofunktionelle sammensætninger
DK3289876T3 (da) Forbindelser til behandling af cancer
DK2445912T3 (da) Ny forbindelse anvendelig til behandlingen af degenerative og inflammatoriske sygdomme
DK2504451T3 (da) Fremgangsmåder til at forudsige det kliniske forløb af cancer
DK3246042T3 (da) Lægemiddelresistent immunterapi til behandling af cancer
DK2567690T3 (da) Anvendelse af amisulphrid til behandling af kemoterapi-induceret kvalme og opkast
AT507702A3 (de) Detektorfläche
DK3443957T3 (da) Forbindelser og sammensætninger til behandling af cancer
DK2452189T3 (da) Fremgangsmåde til identifikation af forbindelser til behandling af cancer
DK2479559T3 (da) Strålingsdekteteringsanordning
DK2451482T3 (da) Kombinationsterapi til behandlingen af diabetes
DK2805746T3 (da) Alkylamido-forbindelser og anvendelser deraf